|Bid||0.9822 x 900|
|Ask||0.9900 x 900|
|Day's range||0.9800 - 1.0100|
|52-week range||0.7500 - 2.9400|
|Beta (5Y monthly)||0.88|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.00|
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
LOS ANGELES, August 06, 2021--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
AcelRx Pharmaceuticals, Inc. ( NASDAQ:ACRX ) is possibly approaching a major achievement in its business, so we would...